Company: XOMAP
Filing Date: 2025-08-15
Form Type: SC TO-T
Source: 0001193125-25-181352
Chunk: 2

Company: XOMA Royalty Corp
Filing Date: 2025-08-15
Form: SC TO-T
Chunk 2
---
 incorporated herein by reference.

| ITEM 2. | SUBJECT COMPANY INFORMATION. |

The subject company and the issuer of the securities subject to the Offer is LAVA Therapeutics N.V., a public limited liability company ( naamloze vennootschap) organized under the laws of the Netherlands, having its corporate seat ( statutaire zetel) in Utrecht, the Netherlands, registered with the Dutch trade register under number 65335740. For purposes of compliance with applicable requirements of the Securities Act of 1933, as amended, and Securities Exchange Act of 1934, as amended, any shareholder communication required to be sent to LAVA’s principal executive offices may be sent to LAVA Therapeutics N.V., Yalelaan 62, 3584 CM Utrecht, the Netherlands. LAVA’s telephone number is (800) 311-6892. This Schedule TO relates to the Shares. According to LAVA, as of the close of business on August 14, 2025, there were: (i) 26,305,295 Shares issued and outstanding, and (ii) 7,712,499 Shares subject to outstanding LAVA Stock Options. The information concerning the principal market on which the Shares are traded, and certain high and low sales prices for the Shares in the principal market in which the Shares are traded set forth in “Special Factors—Section 3. Price Range of Shares; Dividends” of the Offer to Purchase, are incorporated herein by reference.

| ITEM 3. | IDENTITY AND BACKGROUND OF FILING PERSON. |

(a)–(c) The filing company of this Schedule TO is Purchaser. Purchaser’s principal executive office is located at 2200 Powell Street, Suite 310, Emeryville, California 94608. Purchaser’s telephone number is (510) 204-7200.

Purchaser was incorporated in Delaware in 1981 and redomiciled as a Bermuda-exempted company in December 1998. Effective December 31, 2011, Purchaser redomiciled from Bermuda back to Delaware. Purchaser subsequently reincorporated in Nevada on May 30, 2025. Purchaser’s primary business is as a biotech royalty aggregator with a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercialtherapeutic drug candidates. The executive officers of Purchaser are Owen Hughes, its Chief Executive Officer, Tom Burns, its Senior Vice President,